NICE Believes Pembrolizumab Is Worth It in Treatment-Naïve Melanoma Patients
October 9th 2015With the final guidance expected in November, UK will follow Europe in the use of pembrolizumab in treating advanced melanoma patients refractory to previous treatment as well as those who have not been previously treated.
Read More
Weight-Loss Surgery Can Prevent Cancer, Now Let's Pay for It
October 5th 2015The evidence of weight-loss improving overall well-being and predisposition to chronic as well as acute conditions is mounting. We now need coverage policies that can help patients take advantage of weight loss procedures.
Read More
A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures
September 30th 2015The result of a multicollaborative effort, the study published in the Journal of Clinical Oncology found that incorporating breast density information in the risk calculator could accurately estimate women's risk for the disease.
Read More
Results of Gene Panel Test Can Determine Need for Chemotherapy in Breast Cancer
September 28th 2015A prospective study that enrolled more than 10,000 women with hormone-receptor—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy.
Read More
Distinct Molecular Tumor Profile in Younger CRC Patients Recognized
September 28th 2015Data presented at the ongoing European Cancer Congress has identified a different epigenetic profile in the tumors of younger colorectal cancer patients, information that can help improve treatment options in this population.
Read More
Startup's Direct-to-Consumer Genetic Test Receives FDA Attention
September 24th 2015In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.
Read More
Dissecting the Patient Perception of FDA's Breakthrough Designation
September 23rd 2015A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.
Read More
Reimbursement Challenges Persist as Oncologists Embrace Value-Based Care, ACCC Survey Finds
September 21st 2015Among other challenges faced by cancer care centers, reimbursement for providing patient-centered care services remains at the top, a survey by The Association of Community Cancer Centers found.
Read More